TGD has a lot of confidence in the genetic data that they have found. That data is being put to the test to prove its legitimacy in the current AD trial.
If the AD trial bears out the current hypothesis, the claim to precision medicine will be fully supported.
It seems likely to me that the company has additional information about dosing that it hasn't made public pending the AD trial results. If there are dosing decisions that can be made related to the WT gene VS the mutated gene, that would indeed be precision medicine.
News 
Market Data 
Discover 
AI
